Department of Cancer Research
Our vision is to impact on patients’ life by advancing the fight against cancer. Based on strong scientific track-records, we focus on priority research areas and provide research expertise covering the most common and/or malignant cancer types representing a health burden in Luxembourg. The department also represents a state-of-the-art training ground for next generation cancer researchers and acts as a reference point for cancer research in Luxembourg.
Mission
The main mission of the Department of Cancer Research is to advance the treatment options of cancer and reduce the cancer burden within the Luxembourg population and beyond. We do so through research excellence in priority areas covering the basic, translational and clinical research landscape to foster personalised medicine programs. Our activities focus on difficult to treat cancers and our teams have dedicated expertise in cancer immunology, the tumour microenvironment, tumor metabolism and neuro-oncology. We explore the cellular and molecular mechanisms of tumor progression using a wide range of state-of-the-art technologies, including multimodal omics technologies (genomics, metabolomics…), advanced immunoprofiling analyses, as well as ex vivo and in vivo imaging modalities leveraging patient data and innovative patient-derived models for cancer research.
- Cancer Metabolism Group
- Cytoskeleton and Cancer Progression
- DNA Repair and Chemoresistance
- In Vivo Imaging
- Luxembourg Centre of Neuropathology
- Multiomics Data Science
- NORLUX Neuro-Oncology Laboratory
- Neuro-Immunology Group
- Translational Radiomics
- Tumor Immunotherapy and Microenvironment
- Tumor Stroma Interactions
Projects & clinical trials
Featured team members
-
Atte
Aalto Postdoctoral Fellow -
Elisabetta
Bartolini PhD -
Titiksha
Basu Postdoctoral Fellow -
Alice
Benoit PhD -
Amandine
Bernard Laboratory Technician -
Andrea Michela
Biolato PhD -
Coralie
Borne Postdoctoral Fellow -
Manon
Bosseler Laboratory Technician
Scientific publications
-
An integrated workflow for phosphopeptide identification in natural killer cells (NK-92MI) and their targets (MDA-MB-231) during immunological synapse formation – 09/02/2023
-
Ultrarapid lytic granule release from CTLs activates Ca2+-dependent synaptic resistance pathways in melanoma cells – 18/02/2022
-
Tumour Immune Evasion is Promoted by Actin Cytoskeleton-Driven Polarization of Inhibitory Signals to the Immunological Synapse – 09/09/2021
-
How natural killer cells avoid self-destruction when killing their targets – 01/08/2021
-
Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling – 24/05/2021
-
Actin Cytoskeleton in Cancer Progression and Metastasis – Part C – 04/05/2021
-
Illuminating the signaling enigma of Carvedilol – 01/03/2021
-
The multiple roles of actin-binding proteins at invadopodia – 01/01/2021
-
Higher Incidence of B Cell Malignancies in Primary Immunodeficiencies – 09/11/2020
-
Actin Cytoskeleton in Cancer Progression and Metastasis – Part B – 12/10/2020
Related News
Forthcoming events
-
🇬🇧 Immunological mechanisms of resistance to CDK4/6 inhibitors in HR+ breast cancer
Lecture Series Cancer Research
Speaker : Dr Lorenzo Galluzzi, PHD
04/04/2023 11:30
-
🇬🇧 Using Spatial Biology & Advanced Image Analysis Solutions to decipher tumour microenvironment and the drivers of cancer progression
Lecture Series Cancer Research
Speaker : Dr Gregory Hamm
06/04/2023 10:00
CANBIO
CANBIO is a doctoral research and training unit (DTU) addressing the clinical problem of tumour progression and recurrence. PhD candidates within CANBIO are engaged in a collaborative and interdisciplinary endeavour to deliver novel insight into tumour escape mechanisms, disease monitoring and large scale data analysis in highly malignant cancers.
i2TRON
TTM is taking a leading role in the coordination of i2TRON, a doctoral training unit (DTU) with a strong focus on developing the new generation of translational scientists, who can turn observations in the laboratory, clinical setting or community into interventions that improve the health of individuals via innovative diagnostics or treatments.
Visit the dedicated webpage for more information:
